Intended for healthcare professionals

Letters Management of long covid

From doctors as patients: a manifesto for tackling persisting symptoms of covid-19

BMJ 2020; 370 doi: (Published 15 September 2020) Cite this as: BMJ 2020;370:m3565
  1. Nisreen A Alwan, associate professor in public health1,
  2. Emily Attree, salaried general practitioner2,
  3. Jennifer Mary Blair, consultant anaesthetist and trust lead for simulation and human factors3,
  4. Debby Bogaert, chair of paediatric medicine, professor of paediatric infectious diseases, and honorary consultant paediatric infectious diseases4,
  5. Mary-Ann Bowen, general practice partner5,
  6. John Boyle, consultant psychiatrist6,
  7. Madeleine Bradman, general practitioner7,
  8. Tracy Ann Briggs, senior lecturer and honorary consultant in clinical genetics8,
  9. Sarah Burns, general practitioner9,
  10. Daniel Campion, travel health physician2,
  11. Katherine Cushing, general practitioner and clinical commissioning group clinical lead for children, young people, and families10,
  12. Brendan Delaney, chair in medical informatics and decision making11,
  13. Chris Dixon, full time general practice partner12,
  14. Grace E Dolman, hepatology specialty trainee year 713,
  15. Caitriona Dynan, consultant radiologist14,
  16. Ian M Frayling, honorary consulting genetic pathologist and president elect151617,
  17. Nell Freeman-Romilly, foundation doctor18,
  18. Iulia Hammond, general practice specialty trainee year 119,
  19. Jenny Judge, consultant forensic psychiatrist20,
  20. Linn Järte, core trainee year 2 anaesthetist21,
  21. Amali Lokugamage, consultant obstetrician and gynaecologist and honorary associate professor22,
  22. Nathalie MacDermott, NIHR academic clinical lecturer and specialty trainee year 7 paediatric infectious diseases23,
  23. Mairi MacKinnon, general practitioner24,
  24. Visita Majithia, salaried general practitioner2,
  25. Tanya Northridge, general practice partner25,
  26. Laura Powell, anaesthetics core trainee year 126,
  27. Clare Rayner, consultant occupational physician27,
  28. Ginevra Read, specialty trainee year 8 psychiatry26,
  29. Ekta Sahu, specialty doctor paediatrics28,
  30. Claudia Shand, retired general practitioner29,
  31. Amy Small, general practice partner and, member303132,
  32. Cara Strachan, general practitioner33,
  33. Jake Suett, staff grade anaesthetist and intensive care doctor34,
  34. Becky Sykes, salaried general practitioner35,
  35. Sharon Taylor, consultant child and adolescent psychiatrist2,
  36. Kevin Thomas, general practitioner36,
  37. Margarita Thomson, general practitioner2,
  38. Alexis Wiltshire, locum general practitioner37,
  39. Victoria Woods, general practitioner38
  1. 1University of Southampton
  2. 2London
  3. 3Epsom and St Helier University Hospitals NHS Trust
  4. 4Centre for Inflammation Research, University of Edinburgh, Edinburgh
  5. 5West Midlands
  6. 6Belfast
  7. 7North Yorkshire
  8. 8University of Manchester
  9. 9Southampton
  10. 10Newcastle
  11. 11Imperial College London
  12. 12Bexhill on Sea
  13. 13Cambridge University Hospitals NHS Foundation Trust
  14. 14Antrim Area Hospital Northern Ireland
  15. 15St Mark’s Hospital, Harrow
  16. 16St Vincent’s Hospital, Dublin
  17. 17Association of Clinical Pathologists
  18. 18Oxford
  19. 19Greater Manchester
  20. 20Surrey and Borders NHS Trust
  21. 21Swansea
  22. 22University College London
  23. 23King’s College London
  24. 24Inverness
  25. 25Brixton Hill Group Practice
  26. 26Severn Deanery
  27. 27Altrincham
  28. 28Coventry
  29. 29Hook, Hampshire
  30. 30Prestonpans Group Practice
  31. 31BMA Scottish Council
  32. 32BMA Scottish GP Committee
  33. 33East Lothian
  34. 34Queen Elizabeth Hospital King’s Lynn
  35. 35Bristol
  36. 36Pontcae Medical Practice, Merthyr Tydfil
  37. 37Liverpool
  38. 38Chandler’s Ford
  1. jakesuett{at}

We write as a group of doctors affected by persisting symptoms of suspected or confirmed covid-19. We aim to share our insights from both personal experience of the illness and our perspective as physicians.

Tackling this problem will involve collaboration between politicians, healthcare services, public health professionals, scientists, and society. We call for the following principles to be used so that the best possible outcomes can be achieved for all people affected by persisting symptoms of covid-19.

  • Research and surveillance—persisting symptoms of covid-19 should be dealt with using a scientific methodology and without bias. People experiencing them should be counted.

The effects of the virus should be studied in the way that any other disease would be, with thorough attention paid to epidemiology, pathophysiology, and management. “We still know very little about covid-19, but we do know that we cannot fight what we do not measure.”1 Research and surveillance need to capture the full spectrum of disease, including in those not admitted to hospital and not tested, to build an accurate picture of covid-19 phenotypes. We need a clear definition for recovery from covid-19. While further evidence is awaited, clinicians should “be open about uncertainty and transparent in the ways in which we acknowledge the limitations of the imperfect data we have no choice but to use.”2 We argue that this means accepting an emerging picture that prolonged symptoms are having a substantial impact on a significant minority of people and acknowledging that death is not the only outcome to measure. We argue that further research into chronic covid-19 symptoms is essential. Failure to understand the underlying biological mechanisms causing these persisting symptoms risks missing opportunities to identify risk factors, prevent chronicity, and find treatment approaches for people affected now and in the future.

  • Clinical services—services need to be timely, tailored to individuals’ presentations, and involve investigating and treating pathology, as well as the functional recovery of individuals.

Many patients who may, under normal circumstances, have been admitted to hospital instead managed their extremely difficult symptoms at home during this crisis. We should not assume that pathology is different between patients who were admitted to hospital and those who were not. Before any active rehabilitation can start, organic pathology needs to be detected and managed with appropriate investigations. A rehabilitation prescription can then be made for the individual. As Lynne Turner-Stokes, consultant in rehabilitation medicine, warned in a recent Royal Society of Medicine webinar,3 “Before we get people exercising, it’s important to be sure that it’s going to be safe. We need proper evaluation of cardiac and respiratory function, and we need to take things slowly and in a paced measure.” A recent study in JAMA4 of 100 patients (67 of whom had not been admitted to hospital) undergoing cardiac MRI after covid-19 found “cardiac involvement in 78 patients (78%) and ongoing myocardial inflammation in 60 patients (60%).” The authors say that participants “with mostly home based recovery had frequent cardiac inflammatory involvement, which was similar to the hospitalised subgroup with regards to severity and extent.”

The establishment of one-stop clinics will allow pattern recognition and expertise to develop among clinicians identifying and managing sequelae of covid-19. These clinics should reflect the multisystem nature of covid-19 and involve multidisciplinary teams with access to relevant investigations to detect known complications of covid-19 as indicated after clinical review. A reliance on “one size fits all” online rehabilitation services risks serious harm to patients if pathology goes undetected and is a missed opportunity for clinicians to develop their experience with the sequelae of this virus that is set to be an ongoing presence in our clinical practice. Where current guidance has been issued, such as the statement from the National Institute for Health and Care Excellence5 cautioning against graded exercise therapy in the context of covid-19, it should be communicated quickly to clinicians on the front line.

  • Patient involvement—patients must be involved in the commissioning of clinical services and the design of research studies.

“No decision without me”6—lessons learnt from other illnesses have shown the importance of involving those most affected. Patients experiencing persisting symptoms of covid-197 have a great deal to contribute to the search for solutions. Involving patients in research design8 and the commissioning of clinical services will ensure that the patient perspective is listened to and will optimise the development of such studies and clinical services. This may take the form of representatives from patient formed groups, which may include signatories of this letter, liaising with policy makers, researchers, and healthcare leaders.

  • Access to services—clinical services commissioned should not unfairly discriminate against those with negative tests and a clinical diagnosis should be adequate for accessing any appropriate services.

Widespread testing was not available in the early days of the pandemic. The timing of tests for active covid-19 infection (such as RT-PCR tests) affects test performance, and even if performed at an optimal time, the test is associated with a considerable risk of false negatives.9 We know antibody tests have mainly been validated in patients in hospital and are poorly sensitive early in the illness.10 There are few data regarding testing later in the disease course, and false negatives seem to be common. Some people do not seroconvert11 despite having previously tested positive. Thus, adherence to positive test results as a criterion for access to medical services or specific covid-19 sick pay arrangements with employers is unacceptable in the context of a clinical diagnosis of covid-19.

We welcome increasing awareness of the problem of persisting symptoms of COVID-19.12 As politicians, scientists, and doctors attempt to tackle this issue, these principles can act as a guide enabling the experiences of those with the condition to inform the efforts of experts and lead to improved research and clinical care, benefiting those affected and society as a whole.


  • Competing interests: DC reports personal fees from Emergent BioSolutions, outside the submitted work; NM reports grants from National Institute for Health Research UK and grants from the Wellcome Trust, outside the submitted work; MT is cancer clinical lead of South West London CCG (Merton).

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.